KR20080091948A - 락탐형 피리딘 화합물을 포함하는 허혈성 질환의 예방 및치료용 약학조성물 - Google Patents

락탐형 피리딘 화합물을 포함하는 허혈성 질환의 예방 및치료용 약학조성물 Download PDF

Info

Publication number: KR20080091948A
Authority: KR; South Korea
Prior art keywords: compound; naphthyridin; phenyl; methyl; fluoro
Prior art date: 2007-04-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

KR1020070035074A

Other languages

English (en)

Korean (ko)

Inventor

조용백

이준원

이정범

이남규

이봉용

황기철

임소연

장우철

정지형

이병호

서호원

Original Assignee

에스케이케미칼주식회사

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-04-10

Filing date

2007-04-10

Publication date

2008-10-15

2007-04-10 Application filed by 에스케이케미칼주식회사 filed Critical 에스케이케미칼주식회사

2007-04-10 Priority to KR1020070035074A priority Critical patent/KR20080091948A/ko

2008-04-10 Priority to PCT/KR2008/002029 priority patent/WO2008123755A1/fr

2008-10-15 Publication of KR20080091948A publication Critical patent/KR20080091948A/ko

Status Ceased legal-status Critical Current

Links

208000023589 ischemic disease Diseases 0.000 title claims abstract description 26
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 10
230000002265 prevention Effects 0.000 title claims abstract description 7
-1 pyridine compound Chemical class 0.000 title claims description 48
JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title claims description 16
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 title claims description 14
150000003951 lactams Chemical class 0.000 title claims description 4
150000001875 compounds Chemical class 0.000 claims abstract description 277
150000003839 salts Chemical class 0.000 claims abstract description 9
125000001072 heteroaryl group Chemical group 0.000 claims description 33
125000000623 heterocyclic group Chemical group 0.000 claims description 30
239000003814 drug Substances 0.000 claims description 24
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
229910052739 hydrogen Inorganic materials 0.000 claims description 19
230000000302 ischemic effect Effects 0.000 claims description 19
125000003118 aryl group Chemical group 0.000 claims description 18
239000001257 hydrogen Substances 0.000 claims description 18
125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 18
229940079593 drug Drugs 0.000 claims description 17
125000002252 acyl group Chemical group 0.000 claims description 15
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 15
125000001424 substituent group Chemical group 0.000 claims description 12
238000000034 method Methods 0.000 claims description 10
125000006763 (C3-C9) cycloalkyl group Chemical group 0.000 claims description 9
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 9
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 9
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 9
125000005843 halogen group Chemical group 0.000 claims description 9
239000003795 chemical substances by application Substances 0.000 claims description 7
229910052760 oxygen Inorganic materials 0.000 claims description 7
125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 6
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 6
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 6
125000000217 alkyl group Chemical group 0.000 claims description 6
125000004104 aryloxy group Chemical group 0.000 claims description 6
150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 6
125000005842 heteroatom Chemical group 0.000 claims description 6
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
208000010125 myocardial infarction Diseases 0.000 claims description 6
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
208000031225 myocardial ischemia Diseases 0.000 claims description 5
239000001301 oxygen Substances 0.000 claims description 5
239000000126 substance Substances 0.000 claims description 5
208000026106 cerebrovascular disease Diseases 0.000 claims description 4
229910052757 nitrogen Inorganic materials 0.000 claims description 4
229920006395 saturated elastomer Polymers 0.000 claims description 4
GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 claims description 3
SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 claims description 3
GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 claims description 3
YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 claims description 3
VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 claims description 3
ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 claims description 3
WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 claims description 3
FNHHVPPSBFQMEL-KQHDFZBMSA-N (3S)-5-N-[(1S,5R)-3-hydroxy-6-bicyclo[3.1.0]hexanyl]-7-N,3-dimethyl-3-phenyl-2H-1-benzofuran-5,7-dicarboxamide Chemical compound CNC(=O)c1cc(cc2c1OC[C@@]2(C)c1ccccc1)C(=O)NC1[C@H]2CC(O)C[C@@H]12 FNHHVPPSBFQMEL-KQHDFZBMSA-N 0.000 claims description 3
IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 claims description 3
OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 claims description 3
MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 claims description 3
YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 claims description 3
125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims description 3
125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 3
125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 3
125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 claims description 3
125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 3
FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 claims description 3
MHSLDASSAFCCDO-UHFFFAOYSA-N 1-(5-tert-butyl-2-methylpyrazol-3-yl)-3-(4-pyridin-4-yloxyphenyl)urea Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=NC=C1 MHSLDASSAFCCDO-UHFFFAOYSA-N 0.000 claims description 3
WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 claims description 3
ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 claims description 3
YSTQFQQQNHSSGK-UHFFFAOYSA-N 2,6-bis(4-fluorophenyl)-8-methyl-2,7-naphthyridin-1-one Chemical compound O=C1C=2C(C)=NC(C=3C=CC(F)=CC=3)=CC=2C=CN1C1=CC=C(F)C=C1 YSTQFQQQNHSSGK-UHFFFAOYSA-N 0.000 claims description 3
CZUHAPXJOJTVPI-UHFFFAOYSA-N 2,6-diethyl-8-piperidin-1-yl-2,7-naphthyridin-1-one Chemical compound N=1C(CC)=CC=2C=CN(CC)C(=O)C=2C=1N1CCCCC1 CZUHAPXJOJTVPI-UHFFFAOYSA-N 0.000 claims description 3
WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 claims description 3
BKSFWNSBRYKGDX-UHFFFAOYSA-N 2,8-diethyl-6-methyl-2,7-naphthyridin-1-one Chemical compound C1=CN(CC)C(=O)C2=C1C=C(C)N=C2CC BKSFWNSBRYKGDX-UHFFFAOYSA-N 0.000 claims description 3
IFCKRCRMKGDNKV-UHFFFAOYSA-N 2,8-dimethyl-6-phenyl-2,7-naphthyridin-1-one Chemical compound C=1C=2C=CN(C)C(=O)C=2C(C)=NC=1C1=CC=CC=C1 IFCKRCRMKGDNKV-UHFFFAOYSA-N 0.000 claims description 3
OHDJFLAEDQXBQW-UHFFFAOYSA-N 2,8-dimethyl-6-phenyl-3,4-dihydro-2,7-naphthyridin-1-one Chemical compound N=1C(C)=C2C(=O)N(C)CCC2=CC=1C1=CC=CC=C1 OHDJFLAEDQXBQW-UHFFFAOYSA-N 0.000 claims description 3
VCUXVXLUOHDHKK-UHFFFAOYSA-N 2-(2-aminopyrimidin-4-yl)-4-(2-chloro-4-methoxyphenyl)-1,3-thiazole-5-carboxamide Chemical compound ClC1=CC(OC)=CC=C1C1=C(C(N)=O)SC(C=2N=C(N)N=CC=2)=N1 VCUXVXLUOHDHKK-UHFFFAOYSA-N 0.000 claims description 3
XKFMUQNCICTADG-UHFFFAOYSA-N 2-(2-methoxyethyl)-8-piperidin-1-yl-6-propan-2-yl-2,7-naphthyridin-1-one Chemical compound C=12C(=O)N(CCOC)C=CC2=CC(C(C)C)=NC=1N1CCCCC1 XKFMUQNCICTADG-UHFFFAOYSA-N 0.000 claims description 3
HDTMHFXXBNZQGA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-6-(4-fluorophenyl)-8-methyl-2,7-naphthyridin-1-one Chemical compound C1=C(OC)C(OC)=CC=C1N1C(=O)C2=C(C)N=C(C=3C=CC(F)=CC=3)C=C2C=C1 HDTMHFXXBNZQGA-UHFFFAOYSA-N 0.000 claims description 3
AHZJSAWCKUFZNG-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-8-(4-fluorophenyl)-6-methyl-2,7-naphthyridin-1-one Chemical compound C1=C(OC)C(OC)=CC=C1N1C(=O)C2=C(C=3C=CC(F)=CC=3)N=C(C)C=C2C=C1 AHZJSAWCKUFZNG-UHFFFAOYSA-N 0.000 claims description 3
VYKFOCGRMRTEAE-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-8-methyl-6-phenyl-2,7-naphthyridin-1-one Chemical compound C1=C(OC)C(OC)=CC=C1N1C(=O)C2=C(C)N=C(C=3C=CC=CC=3)C=C2C=C1 VYKFOCGRMRTEAE-UHFFFAOYSA-N 0.000 claims description 3
QPRKKJGYJRUKAN-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-8-piperidin-1-yl-6-propan-2-yl-2,7-naphthyridin-1-one Chemical compound C1=C(OC)C(OC)=CC=C1N1C(=O)C2=C(N3CCCCC3)N=C(C(C)C)C=C2C=C1 QPRKKJGYJRUKAN-UHFFFAOYSA-N 0.000 claims description 3
PRUSMDHOZTXOHG-UHFFFAOYSA-N 2-(3,5-dichlorophenyl)-6-(3,4-difluorophenyl)-8-methyl-2,7-naphthyridin-1-one Chemical compound O=C1C=2C(C)=NC(C=3C=C(F)C(F)=CC=3)=CC=2C=CN1C1=CC(Cl)=CC(Cl)=C1 PRUSMDHOZTXOHG-UHFFFAOYSA-N 0.000 claims description 3
RFQFFUFJYQROEH-UHFFFAOYSA-N 2-(3,5-dichlorophenyl)-6-(4-fluorophenyl)-8-methyl-2,7-naphthyridin-1-one Chemical compound O=C1C=2C(C)=NC(C=3C=CC(F)=CC=3)=CC=2C=CN1C1=CC(Cl)=CC(Cl)=C1 RFQFFUFJYQROEH-UHFFFAOYSA-N 0.000 claims description 3
HAMPPDUAUQPICZ-UHFFFAOYSA-N 2-(3,5-dichlorophenyl)-8-methyl-6-phenyl-2,7-naphthyridin-1-one Chemical compound O=C1C=2C(C)=NC(C=3C=CC=CC=3)=CC=2C=CN1C1=CC(Cl)=CC(Cl)=C1 HAMPPDUAUQPICZ-UHFFFAOYSA-N 0.000 claims description 3
OHPMLUCAOSYJBU-UHFFFAOYSA-N 2-(3,5-difluorophenyl)-6-(4-fluorophenyl)-8-methyl-2,7-naphthyridin-1-one Chemical compound O=C1C=2C(C)=NC(C=3C=CC(F)=CC=3)=CC=2C=CN1C1=CC(F)=CC(F)=C1 OHPMLUCAOSYJBU-UHFFFAOYSA-N 0.000 claims description 3
YJTFWJTUCBXTFW-UHFFFAOYSA-N 2-(3,5-difluorophenyl)-8-(4-fluorophenyl)-6-methyl-2,7-naphthyridin-1-one Chemical compound O=C1C=2C(C=3C=CC(F)=CC=3)=NC(C)=CC=2C=CN1C1=CC(F)=CC(F)=C1 YJTFWJTUCBXTFW-UHFFFAOYSA-N 0.000 claims description 3
SXHJYCKCEGVBJA-UHFFFAOYSA-N 2-(3,5-difluorophenyl)-8-methyl-6-phenyl-2,7-naphthyridin-1-one Chemical compound O=C1C=2C(C)=NC(C=3C=CC=CC=3)=CC=2C=CN1C1=CC(F)=CC(F)=C1 SXHJYCKCEGVBJA-UHFFFAOYSA-N 0.000 claims description 3
XCSPLLRDGUYQOV-UHFFFAOYSA-N 2-(4-fluorophenyl)-8-methyl-6-phenyl-2,7-naphthyridin-1-one Chemical compound O=C1C=2C(C)=NC(C=3C=CC=CC=3)=CC=2C=CN1C1=CC=C(F)C=C1 XCSPLLRDGUYQOV-UHFFFAOYSA-N 0.000 claims description 3
ZAXOXQIDDHGYQG-UHFFFAOYSA-N 2-(4-fluorophenyl)-8-piperidin-1-yl-6-propan-2-yl-2,7-naphthyridin-1-one Chemical compound O=C1C=2C(N3CCCCC3)=NC(C(C)C)=CC=2C=CN1C1=CC=C(F)C=C1 ZAXOXQIDDHGYQG-UHFFFAOYSA-N 0.000 claims description 3
WWHBKTPSTOCXPW-UHFFFAOYSA-N 2-[(4-methoxyphenyl)methyl]-3,4-dihydro-2,7-naphthyridin-1-one Chemical compound C1=CC(OC)=CC=C1CN1C(=O)C2=CN=CC=C2CC1 WWHBKTPSTOCXPW-UHFFFAOYSA-N 0.000 claims description 3
OTULQFMRRISFHY-UHFFFAOYSA-N 2-[2-(dimethylamino)ethyl]-8-(4-fluorophenyl)-6-methyl-3,4-dihydro-2,7-naphthyridin-1-one Chemical compound C=12C(=O)N(CCN(C)C)CCC2=CC(C)=NC=1C1=CC=C(F)C=C1 OTULQFMRRISFHY-UHFFFAOYSA-N 0.000 claims description 3
PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 claims description 3
SYLOAFKIKQJIQJ-UHFFFAOYSA-N 2-[8-(4-fluorophenyl)-6-methyl-1-oxo-3,4-dihydro-2,7-naphthyridin-2-yl]acetic acid Chemical compound N=1C(C)=CC=2CCN(CC(O)=O)C(=O)C=2C=1C1=CC=C(F)C=C1 SYLOAFKIKQJIQJ-UHFFFAOYSA-N 0.000 claims description 3
VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 claims description 3
GMBBTHAIMKHPQU-UHFFFAOYSA-N 2-benzyl-2,7-naphthyridin-1-one Chemical compound C1=CC2=CC=NC=C2C(=O)N1CC1=CC=CC=C1 GMBBTHAIMKHPQU-UHFFFAOYSA-N 0.000 claims description 3
HJQKGYUXRJSBBM-UHFFFAOYSA-N 2-benzyl-3,4-dihydro-2,7-naphthyridin-1-one Chemical compound C1CC2=CC=NC=C2C(=O)N1CC1=CC=CC=C1 HJQKGYUXRJSBBM-UHFFFAOYSA-N 0.000 claims description 3
ZYRWGCHRWBNZBW-UHFFFAOYSA-N 2-benzyl-8-methyl-6-phenyl-2,7-naphthyridin-1-one Chemical compound O=C1C=2C(C)=NC(C=3C=CC=CC=3)=CC=2C=CN1CC1=CC=CC=C1 ZYRWGCHRWBNZBW-UHFFFAOYSA-N 0.000 claims description 3
FGDKUDJCALINIS-UHFFFAOYSA-N 2-benzyl-8-methyl-6-phenyl-3,4-dihydro-2,7-naphthyridin-1-one Chemical compound O=C1C=2C(C)=NC(C=3C=CC=CC=3)=CC=2CCN1CC1=CC=CC=C1 FGDKUDJCALINIS-UHFFFAOYSA-N 0.000 claims description 3
YQTGKCWJQPWTEE-UHFFFAOYSA-N 2-ethyl-6,8-dimethyl-2,7-naphthyridin-1-one Chemical compound CC1=NC(C)=C2C(=O)N(CC)C=CC2=C1 YQTGKCWJQPWTEE-UHFFFAOYSA-N 0.000 claims description 3
LEPCLEIJBHWHCA-UHFFFAOYSA-N 2-ethyl-6-(4-fluorophenyl)-8-methyl-2,7-naphthyridin-1-one Chemical compound N=1C(C)=C2C(=O)N(CC)C=CC2=CC=1C1=CC=C(F)C=C1 LEPCLEIJBHWHCA-UHFFFAOYSA-N 0.000 claims description 3
QCSJHGZQBYANGT-UHFFFAOYSA-N 2-ethyl-6-methyl-8-(oxolan-2-yl)-3,4-dihydro-2,7-naphthyridin-1-one Chemical compound C=12C(=O)N(CC)CCC2=CC(C)=NC=1C1CCCO1 QCSJHGZQBYANGT-UHFFFAOYSA-N 0.000 claims description 3
QMUPNIRQEUNQTL-UHFFFAOYSA-N 2-ethyl-6-methyl-8-propan-2-yl-2,7-naphthyridin-1-one Chemical compound CC1=NC(C(C)C)=C2C(=O)N(CC)C=CC2=C1 QMUPNIRQEUNQTL-UHFFFAOYSA-N 0.000 claims description 3
ZQEPBRUNLHUZFE-UHFFFAOYSA-N 2-ethyl-8-(4-fluorophenyl)-6-methyl-2,7-naphthyridin-1-one Chemical compound C=12C(=O)N(CC)C=CC2=CC(C)=NC=1C1=CC=C(F)C=C1 ZQEPBRUNLHUZFE-UHFFFAOYSA-N 0.000 claims description 3
RHUGZMNGAJDGBN-UHFFFAOYSA-N 2-ethyl-8-(4-fluorophenyl)-6-methyl-3,4-dihydro-2,7-naphthyridin-1-one Chemical compound C=12C(=O)N(CC)CCC2=CC(C)=NC=1C1=CC=C(F)C=C1 RHUGZMNGAJDGBN-UHFFFAOYSA-N 0.000 claims description 3
DVDREQIBLHSESK-UHFFFAOYSA-N 2-ethyl-8-(furan-2-yl)-6-methyl-2,7-naphthyridin-1-one Chemical compound C=12C(=O)N(CC)C=CC2=CC(C)=NC=1C1=CC=CO1 DVDREQIBLHSESK-UHFFFAOYSA-N 0.000 claims description 3
AAWZDFHQBQLWPT-UHFFFAOYSA-N 2-ethyl-8-methyl-6-phenyl-2,7-naphthyridin-1-one Chemical compound N=1C(C)=C2C(=O)N(CC)C=CC2=CC=1C1=CC=CC=C1 AAWZDFHQBQLWPT-UHFFFAOYSA-N 0.000 claims description 3
JXYDLGSNANQIIG-UHFFFAOYSA-N 2-ethyl-8-methyl-6-phenyl-3,4-dihydro-2,7-naphthyridin-1-one Chemical compound N=1C(C)=C2C(=O)N(CC)CCC2=CC=1C1=CC=CC=C1 JXYDLGSNANQIIG-UHFFFAOYSA-N 0.000 claims description 3
MJRWFZGMCLRUSO-UHFFFAOYSA-N 2-ethyl-8-piperidin-1-yl-6-propan-2-yl-2,7-naphthyridin-1-one Chemical compound C=12C(=O)N(CC)C=CC2=CC(C(C)C)=NC=1N1CCCCC1 MJRWFZGMCLRUSO-UHFFFAOYSA-N 0.000 claims description 3
LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 claims description 3
GCCFYOUSCICNCD-UHFFFAOYSA-N 2h-2,7-naphthyridin-1-one Chemical compound C1=NC=C2C(O)=NC=CC2=C1 GCCFYOUSCICNCD-UHFFFAOYSA-N 0.000 claims description 3
YGVQSZGFKBWCLY-UHFFFAOYSA-N 3,4-dihydro-2h-2,7-naphthyridin-1-one Chemical compound C1=NC=C2C(=O)NCCC2=C1 YGVQSZGFKBWCLY-UHFFFAOYSA-N 0.000 claims description 3
QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 claims description 3
CEPGBKUODCKVHK-UHFFFAOYSA-N 3-[8-(4-fluorophenyl)-6-methyl-1-oxo-2,7-naphthyridin-2-yl]propanoic acid Chemical compound N=1C(C)=CC=2C=CN(CCC(O)=O)C(=O)C=2C=1C1=CC=C(F)C=C1 CEPGBKUODCKVHK-UHFFFAOYSA-N 0.000 claims description 3
GIILRFOFEZTAPQ-UHFFFAOYSA-N 3-phenyl-3,4-dihydro-2h-2,7-naphthyridin-1-one Chemical compound C1C2=CC=NC=C2C(=O)NC1C1=CC=CC=C1 GIILRFOFEZTAPQ-UHFFFAOYSA-N 0.000 claims description 3
WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 claims description 3
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 3
XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 claims description 3
TUDYLJJPFGKGNN-UHFFFAOYSA-N 6-(3,4-difluorophenyl)-2,8-dimethyl-2,7-naphthyridin-1-one Chemical compound C=1C=2C=CN(C)C(=O)C=2C(C)=NC=1C1=CC=C(F)C(F)=C1 TUDYLJJPFGKGNN-UHFFFAOYSA-N 0.000 claims description 3
XUVZHKUWXOXUOO-UHFFFAOYSA-N 6-(3,4-difluorophenyl)-2-(3,4-dimethoxyphenyl)-8-methyl-2,7-naphthyridin-1-one Chemical compound C1=C(OC)C(OC)=CC=C1N1C(=O)C2=C(C)N=C(C=3C=C(F)C(F)=CC=3)C=C2C=C1 XUVZHKUWXOXUOO-UHFFFAOYSA-N 0.000 claims description 3
ZWVILINJPPJWCC-UHFFFAOYSA-N 6-(3,4-difluorophenyl)-2-(3,5-difluorophenyl)-8-methyl-2,7-naphthyridin-1-one Chemical compound O=C1C=2C(C)=NC(C=3C=C(F)C(F)=CC=3)=CC=2C=CN1C1=CC(F)=CC(F)=C1 ZWVILINJPPJWCC-UHFFFAOYSA-N 0.000 claims description 3
RJLVLGJVROZCKH-UHFFFAOYSA-N 6-(3,4-difluorophenyl)-2-(4-fluorophenyl)-8-methyl-2,7-naphthyridin-1-one Chemical compound O=C1C=2C(C)=NC(C=3C=C(F)C(F)=CC=3)=CC=2C=CN1C1=CC=C(F)C=C1 RJLVLGJVROZCKH-UHFFFAOYSA-N 0.000 claims description 3
BCMLARVEIJOSLL-UHFFFAOYSA-N 6-(3,4-difluorophenyl)-2-ethyl-8-methyl-2,7-naphthyridin-1-one Chemical compound N=1C(C)=C2C(=O)N(CC)C=CC2=CC=1C1=CC=C(F)C(F)=C1 BCMLARVEIJOSLL-UHFFFAOYSA-N 0.000 claims description 3
PMFOLXHYJIRNSX-UHFFFAOYSA-N 6-(3,4-difluorophenyl)-8-methyl-2h-2,7-naphthyridin-1-one Chemical compound C=1C=2C=CNC(=O)C=2C(C)=NC=1C1=CC=C(F)C(F)=C1 PMFOLXHYJIRNSX-UHFFFAOYSA-N 0.000 claims description 3
RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 claims description 3
YLKXMHJXZRKOME-UHFFFAOYSA-N 6-(4-fluorophenyl)-2,8-dimethyl-2,7-naphthyridin-1-one Chemical compound C=1C=2C=CN(C)C(=O)C=2C(C)=NC=1C1=CC=C(F)C=C1 YLKXMHJXZRKOME-UHFFFAOYSA-N 0.000 claims description 3
MUFVJZOVVZCCBY-UHFFFAOYSA-N 6-(4-fluorophenyl)-8-methyl-2h-2,7-naphthyridin-1-one Chemical compound C=1C=2C=CNC(=O)C=2C(C)=NC=1C1=CC=C(F)C=C1 MUFVJZOVVZCCBY-UHFFFAOYSA-N 0.000 claims description 3
FFGJRRYXYJBLRP-UHFFFAOYSA-N 6-ethyl-2-methyl-8-piperidin-1-yl-2,7-naphthyridin-1-one Chemical compound N=1C(CC)=CC=2C=CN(C)C(=O)C=2C=1N1CCCCC1 FFGJRRYXYJBLRP-UHFFFAOYSA-N 0.000 claims description 3
CZFLLPCKKNHQJJ-UHFFFAOYSA-N 6-ethyl-8-piperidin-1-yl-2h-2,7-naphthyridin-1-one Chemical compound N=1C(CC)=CC=2C=CNC(=O)C=2C=1N1CCCCC1 CZFLLPCKKNHQJJ-UHFFFAOYSA-N 0.000 claims description 3
AQRXWIRFYHZJRU-UHFFFAOYSA-N 6-tert-butyl-2-(3,4-dimethoxyphenyl)-8-piperidin-1-yl-2,7-naphthyridin-1-one Chemical compound C1=C(OC)C(OC)=CC=C1N1C(=O)C2=C(N3CCCCC3)N=C(C(C)(C)C)C=C2C=C1 AQRXWIRFYHZJRU-UHFFFAOYSA-N 0.000 claims description 3
YRCQNMAENZNNCI-UHFFFAOYSA-N 6-tert-butyl-2-(4-fluorophenyl)-8-piperidin-1-yl-2,7-naphthyridin-1-one Chemical compound O=C1C=2C(N3CCCCC3)=NC(C(C)(C)C)=CC=2C=CN1C1=CC=C(F)C=C1 YRCQNMAENZNNCI-UHFFFAOYSA-N 0.000 claims description 3
MJETYBIOHSJPKF-UHFFFAOYSA-N 6-tert-butyl-2-ethyl-8-piperidin-1-yl-2,7-naphthyridin-1-one Chemical compound C=12C(=O)N(CC)C=CC2=CC(C(C)(C)C)=NC=1N1CCCCC1 MJETYBIOHSJPKF-UHFFFAOYSA-N 0.000 claims description 3
WFHQWEHJVRVGLY-UHFFFAOYSA-N 6-tert-butyl-2-methyl-8-piperidin-1-yl-2,7-naphthyridin-1-one Chemical compound C=12C(=O)N(C)C=CC2=CC(C(C)(C)C)=NC=1N1CCCCC1 WFHQWEHJVRVGLY-UHFFFAOYSA-N 0.000 claims description 3
ZDSWKVCGHDHQDJ-UHFFFAOYSA-N 6-tert-butyl-8-piperidin-1-yl-2h-2,7-naphthyridin-1-one Chemical compound N=1C(C(C)(C)C)=CC=2C=CNC(=O)C=2C=1N1CCCCC1 ZDSWKVCGHDHQDJ-UHFFFAOYSA-N 0.000 claims description 3
MZLODNIZIDLCLT-UHFFFAOYSA-N 8-(4-fluorophenyl)-2,6-dimethyl-2,7-naphthyridin-1-one Chemical compound N=1C(C)=CC=2C=CN(C)C(=O)C=2C=1C1=CC=C(F)C=C1 MZLODNIZIDLCLT-UHFFFAOYSA-N 0.000 claims description 3
HMKURTVVKYOYOC-UHFFFAOYSA-N 8-(4-fluorophenyl)-2,6-dimethyl-3,4-dihydro-2,7-naphthyridin-1-one Chemical compound C=12C(=O)N(C)CCC2=CC(C)=NC=1C1=CC=C(F)C=C1 HMKURTVVKYOYOC-UHFFFAOYSA-N 0.000 claims description 3
WOYIMBCPXKDTJS-UHFFFAOYSA-N 8-(4-fluorophenyl)-2-(2-hydroxyethyl)-6-methyl-3,4-dihydro-2,7-naphthyridin-1-one Chemical compound N=1C(C)=CC=2CCN(CCO)C(=O)C=2C=1C1=CC=C(F)C=C1 WOYIMBCPXKDTJS-UHFFFAOYSA-N 0.000 claims description 3
RKNVKJPIVJLNLF-UHFFFAOYSA-N 8-(4-fluorophenyl)-6-methyl-1-oxo-2,7-naphthyridine-2-carboxylic acid Chemical compound N=1C(C)=CC=2C=CN(C(O)=O)C(=O)C=2C=1C1=CC=C(F)C=C1 RKNVKJPIVJLNLF-UHFFFAOYSA-N 0.000 claims description 3
VVKVFRAJEXMIRN-UHFFFAOYSA-N 8-(4-fluorophenyl)-6-methyl-2-(2-morpholin-4-ylethyl)-3,4-dihydro-2,7-naphthyridin-1-one Chemical compound O=C1C=2C(C=3C=CC(F)=CC=3)=NC(C)=CC=2CCN1CCN1CCOCC1 VVKVFRAJEXMIRN-UHFFFAOYSA-N 0.000 claims description 3
VJLFNQKFADRDSR-UHFFFAOYSA-N 8-(4-fluorophenyl)-6-methyl-2h-2,7-naphthyridin-1-one Chemical compound N=1C(C)=CC=2C=CNC(=O)C=2C=1C1=CC=C(F)C=C1 VJLFNQKFADRDSR-UHFFFAOYSA-N 0.000 claims description 3
NFNCQGJXUUOSMC-UHFFFAOYSA-N 8-(4-fluorophenyl)-6-methyl-3,4-dihydro-2h-2,7-naphthyridin-1-one Chemical compound N=1C(C)=CC=2CCNC(=O)C=2C=1C1=CC=C(F)C=C1 NFNCQGJXUUOSMC-UHFFFAOYSA-N 0.000 claims description 3
CMVBLLJWZYGXKT-UHFFFAOYSA-N 8-(4-fluoropiperidin-1-yl)-6-methyl-2h-2,7-naphthyridin-1-one Chemical compound N=1C(C)=CC=2C=CNC(=O)C=2C=1N1CCC(F)CC1 CMVBLLJWZYGXKT-UHFFFAOYSA-N 0.000 claims description 3
MRSBJNKMLXKZSZ-UHFFFAOYSA-N 8-cyclohexyl-2-ethyl-6-methyl-2,7-naphthyridin-1-one Chemical compound C=12C(=O)N(CC)C=CC2=CC(C)=NC=1C1CCCCC1 MRSBJNKMLXKZSZ-UHFFFAOYSA-N 0.000 claims description 3
DAGGRPOKFSOKMR-UHFFFAOYSA-N 8-cyclopentyl-2-ethyl-6-methyl-2,7-naphthyridin-1-one Chemical compound C=12C(=O)N(CC)C=CC2=CC(C)=NC=1C1CCCC1 DAGGRPOKFSOKMR-UHFFFAOYSA-N 0.000 claims description 3
QRSNRDIVCXPYAO-UHFFFAOYSA-N 8-cyclopropyl-2-ethyl-6-methyl-2,7-naphthyridin-1-one Chemical compound C=12C(=O)N(CC)C=CC2=CC(C)=NC=1C1CC1 QRSNRDIVCXPYAO-UHFFFAOYSA-N 0.000 claims description 3
FCKNCJUTVLRMRN-UHFFFAOYSA-N 8-methyl-6-phenyl-2h-2,7-naphthyridin-1-one Chemical compound C=1C=2C=CNC(=O)C=2C(C)=NC=1C1=CC=CC=C1 FCKNCJUTVLRMRN-UHFFFAOYSA-N 0.000 claims description 3
TUVINZRZLKGQSJ-UHFFFAOYSA-N 8-piperidin-1-yl-6-propan-2-yl-2h-2,7-naphthyridin-1-one Chemical compound N=1C(C(C)C)=CC=2C=CNC(=O)C=2C=1N1CCCCC1 TUVINZRZLKGQSJ-UHFFFAOYSA-N 0.000 claims description 3
206010002383 Angina Pectoris Diseases 0.000 claims description 3
JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 claims description 3
125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 3
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 3
OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 claims description 3
QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 claims description 3
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 claims description 3
SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 claims description 3
LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 claims description 3
PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 claims description 3
125000003545 alkoxy group Chemical group 0.000 claims description 3
125000003282 alkyl amino group Chemical group 0.000 claims description 3
125000001769 aryl amino group Chemical group 0.000 claims description 3
125000005135 aryl sulfinyl group Chemical group 0.000 claims description 3
125000004657 aryl sulfonyl amino group Chemical group 0.000 claims description 3
125000004391 aryl sulfonyl group Chemical group 0.000 claims description 3
XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 claims description 3
KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 claims description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
208000013677 cerebrovascular dementia Diseases 0.000 claims description 3
229940125773 compound 10 Drugs 0.000 claims description 3
229940126543 compound 14 Drugs 0.000 claims description 3
229940125758 compound 15 Drugs 0.000 claims description 3
229940126142 compound 16 Drugs 0.000 claims description 3
229940125810 compound 20 Drugs 0.000 claims description 3
229940126086 compound 21 Drugs 0.000 claims description 3
229940126208 compound 22 Drugs 0.000 claims description 3
229940125833 compound 23 Drugs 0.000 claims description 3
229940125961 compound 24 Drugs 0.000 claims description 3
229940125846 compound 25 Drugs 0.000 claims description 3
229940127204 compound 29 Drugs 0.000 claims description 3
229940127573 compound 38 Drugs 0.000 claims description 3
229940125844 compound 46 Drugs 0.000 claims description 3
229940127271 compound 49 Drugs 0.000 claims description 3
229940126545 compound 53 Drugs 0.000 claims description 3
229940125900 compound 59 Drugs 0.000 claims description 3
125000004093 cyano group Chemical group *C#N 0.000 claims description 3
125000006310 cycloalkyl amino group Chemical group 0.000 claims description 3
JTOKHMBNDKYUDK-UHFFFAOYSA-N ethyl 2-[8-(4-fluorophenyl)-6-methyl-1-oxo-3,4-dihydro-2,7-naphthyridin-2-yl]acetate Chemical compound C=12C(=O)N(CC(=O)OCC)CCC2=CC(C)=NC=1C1=CC=C(F)C=C1 JTOKHMBNDKYUDK-UHFFFAOYSA-N 0.000 claims description 3
GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 claims description 3
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 claims description 3
QAWZYGKKPUMOTF-UHFFFAOYSA-N methyl 3-[8-(4-fluorophenyl)-6-methyl-1-oxo-2,7-naphthyridin-2-yl]propanoate Chemical compound C=12C(=O)N(CCC(=O)OC)C=CC2=CC(C)=NC=1C1=CC=C(F)C=C1 QAWZYGKKPUMOTF-UHFFFAOYSA-N 0.000 claims description 3
ISEONOIKKANYNA-UHFFFAOYSA-N methyl 8-(4-fluorophenyl)-6-methyl-1-oxo-2,7-naphthyridine-2-carboxylate Chemical compound C=12C(=O)N(C(=O)OC)C=CC2=CC(C)=NC=1C1=CC=C(F)C=C1 ISEONOIKKANYNA-UHFFFAOYSA-N 0.000 claims description 3
ADLVOMMETVWRJF-UHFFFAOYSA-N methyl 8-(4-fluorophenyl)-6-methyl-1-oxo-3,4-dihydro-2,7-naphthyridine-2-carboxylate Chemical compound C=12C(=O)N(C(=O)OC)CCC2=CC(C)=NC=1C1=CC=C(F)C=C1 ADLVOMMETVWRJF-UHFFFAOYSA-N 0.000 claims description 3
ZBELDPMWYXDLNY-UHFFFAOYSA-N methyl 9-(4-bromo-2-fluoroanilino)-[1,3]thiazolo[5,4-f]quinazoline-2-carboximidate Chemical compound C12=C3SC(C(=N)OC)=NC3=CC=C2N=CN=C1NC1=CC=C(Br)C=C1F ZBELDPMWYXDLNY-UHFFFAOYSA-N 0.000 claims description 3
125000001624 naphthyl group Chemical group 0.000 claims description 3
IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 claims description 3
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 claims description 3
AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 claims description 3
229910052717 sulfur Chemical group 0.000 claims description 3
239000011593 sulfur Chemical group 0.000 claims description 3
239000007924 injection Substances 0.000 claims description 2
238000002347 injection Methods 0.000 claims description 2
238000001990 intravenous administration Methods 0.000 claims description 2
238000007920 subcutaneous administration Methods 0.000 claims description 2
239000003826 tablet Substances 0.000 claims description 2
STPKWKPURVSAJF-LJEWAXOPSA-N (4r,5r)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-4-ol Chemical compound O[C@H]1C(CCCC)(CCCC)CS(=O)(=O)C2=CC=C(N(C)C)C=C2[C@H]1C(C=C1)=CC=C1OCC(C=C1)=CC=C1C[N+]1(CC2)CCN2CC1 STPKWKPURVSAJF-LJEWAXOPSA-N 0.000 claims 2
YCJZWBZJSYLMPB-UHFFFAOYSA-N n-(2-chloropyrimidin-4-yl)-2,5-dimethyl-1-phenylimidazole-4-carboxamide Chemical compound CC=1N(C=2C=CC=CC=2)C(C)=NC=1C(=O)NC1=CC=NC(Cl)=N1 YCJZWBZJSYLMPB-UHFFFAOYSA-N 0.000 claims 2
238000007918 intramuscular administration Methods 0.000 claims 1
239000002674 ointment Substances 0.000 claims 1
230000000694 effects Effects 0.000 abstract description 8
230000014509 gene expression Effects 0.000 abstract description 7
230000004094 calcium homeostasis Effects 0.000 abstract description 5
108090000623 proteins and genes Proteins 0.000 abstract description 3
150000003222 pyridines Chemical class 0.000 abstract description 3
230000001120 cytoprotective effect Effects 0.000 abstract description 2
230000035939 shock Effects 0.000 abstract description 2
239000004480 active ingredient Substances 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 23
102000002812 Heat-Shock Proteins Human genes 0.000 description 12
108010004889 Heat-Shock Proteins Proteins 0.000 description 12
239000002609 medium Substances 0.000 description 11
239000000243 solution Substances 0.000 description 10
230000002861 ventricular Effects 0.000 description 10
241000700159 Rattus Species 0.000 description 9
239000011575 calcium Substances 0.000 description 9
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 7
229910052791 calcium Inorganic materials 0.000 description 7
210000004413 cardiac myocyte Anatomy 0.000 description 6
238000011156 evaluation Methods 0.000 description 6
208000028867 ischemia Diseases 0.000 description 6
239000000203 mixture Substances 0.000 description 6
230000010412 perfusion Effects 0.000 description 6
230000001681 protective effect Effects 0.000 description 6
210000001519 tissue Anatomy 0.000 description 6
PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 5
108091003079 Bovine Serum Albumin Proteins 0.000 description 5
230000008859 change Effects 0.000 description 5
239000012091 fetal bovine serum Substances 0.000 description 5
230000003834 intracellular effect Effects 0.000 description 5
WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 4
108020004414 DNA Proteins 0.000 description 4
208000006011 Stroke Diseases 0.000 description 4
238000010171 animal model Methods 0.000 description 4
210000001367 artery Anatomy 0.000 description 4
230000000747 cardiac effect Effects 0.000 description 4
238000009472 formulation Methods 0.000 description 4
230000036722 left ventricular developed pressure Effects 0.000 description 4
238000012360 testing method Methods 0.000 description 4
239000013598 vector Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
102000003855 L-lactate dehydrogenase Human genes 0.000 description 3
108700023483 L-lactate dehydrogenases Proteins 0.000 description 3
230000033228 biological regulation Effects 0.000 description 3
229950004398 broxuridine Drugs 0.000 description 3
230000030833 cell death Effects 0.000 description 3
YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000004624 confocal microscopy Methods 0.000 description 3
230000008828 contractile function Effects 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
230000002107 myocardial effect Effects 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
239000000047 product Substances 0.000 description 3
230000010410 reperfusion Effects 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
206010010904 Convulsion Diseases 0.000 description 2
241000620209 Escherichia coli DH5[alpha] Species 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
229930193140 Neomycin Natural products 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000006907 apoptotic process Effects 0.000 description 2
230000017531 blood circulation Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
210000004351 coronary vessel Anatomy 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000034994 death Effects 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
238000000605 extraction Methods 0.000 description 2
239000012530 fluid Substances 0.000 description 2
210000002064 heart cell Anatomy 0.000 description 2
238000011534 incubation Methods 0.000 description 2
239000007928 intraperitoneal injection Substances 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000007788 liquid Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
229960004927 neomycin Drugs 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000008188 pellet Substances 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
239000011734 sodium Substances 0.000 description 2
238000010186 staining Methods 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
238000005406 washing Methods 0.000 description 2
SRKGZXIJDGWVAI-GVAVTCRGSA-M (e,3r)-7-[6-tert-butyl-4-(4-fluorophenyl)-2-propan-2-ylpyridin-3-yl]-3,5-dihydroxyhept-6-enoate Chemical compound CC(C)C1=NC(C(C)(C)C)=CC(C=2C=CC(F)=CC=2)=C1\C=C\C(O)C[C@@H](O)CC([O-])=O SRKGZXIJDGWVAI-GVAVTCRGSA-M 0.000 description 1
AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
HCCNBKFJYUWLEX-UHFFFAOYSA-N 7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)-3-(pyrazin-2-ylmethylamino)pyrido[3,4-b]pyrazin-2-one Chemical compound O=C1N(CCOCCC)C2=CC(C=3C=NC(OC)=CC=3)=NC=C2N=C1NCC1=CN=CC=N1 HCCNBKFJYUWLEX-UHFFFAOYSA-N 0.000 description 1
101710128948 Adenosine receptor A1 Proteins 0.000 description 1
102100033346 Adenosine receptor A1 Human genes 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
208000014644 Brain disease Diseases 0.000 description 1
108090000312 Calcium Channels Proteins 0.000 description 1
102000003922 Calcium Channels Human genes 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
108091006146 Channels Proteins 0.000 description 1
101710163595 Chaperone protein DnaK Proteins 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
102000011714 Glycine Receptors Human genes 0.000 description 1
108010076533 Glycine Receptors Proteins 0.000 description 1
102000005623 HSP27 Heat-Shock Proteins Human genes 0.000 description 1
108010045100 HSP27 Heat-Shock Proteins Proteins 0.000 description 1
101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
208000032382 Ischaemic stroke Diseases 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
239000008002 Krebs-Henseleit bicarbonate buffer Substances 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
239000005089 Luciferase Substances 0.000 description 1
239000006137 Luria-Bertani broth Substances 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
206010062575 Muscle contracture Diseases 0.000 description 1
102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
102000050381 Na+/H+ exchanger Human genes 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
108091027981 Response element Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
108091006672 Sodium–hydrogen antiporter Proteins 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
229910001413 alkali metal ion Inorganic materials 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
230000002253 anti-ischaemic effect Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127218 antiplatelet drug Drugs 0.000 description 1
239000004019 antithrombin Substances 0.000 description 1
210000000709 aorta Anatomy 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
238000003149 assay kit Methods 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
229940097320 beta blocking agent Drugs 0.000 description 1
239000003130 blood coagulation factor inhibitor Substances 0.000 description 1
201000008247 brain infarction Diseases 0.000 description 1
SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
230000001625 cardiomyogenic effect Effects 0.000 description 1
230000003293 cardioprotective effect Effects 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
210000001627 cerebral artery Anatomy 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
206010008118 cerebral infarction Diseases 0.000 description 1
230000004087 circulation Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000011109 contamination Methods 0.000 description 1
208000006111 contracture Diseases 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
230000035487 diastolic blood pressure Effects 0.000 description 1
230000003205 diastolic effect Effects 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
239000003527 fibrinolytic agent Substances 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
238000002073 fluorescence micrograph Methods 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
210000005240 left ventricle Anatomy 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
208000037891 myocardial injury Diseases 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
239000004090 neuroprotective agent Substances 0.000 description 1
150000002823 nitrates Chemical class 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
239000000106 platelet aggregation inhibitor Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002633 protecting effect Effects 0.000 description 1
230000009993 protective function Effects 0.000 description 1
210000003492 pulmonary vein Anatomy 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
239000000523 sample Substances 0.000 description 1
239000004017 serum-free culture medium Substances 0.000 description 1
238000002791 soaking Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000007447 staining method Methods 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000035488 systolic blood pressure Effects 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229960000103 thrombolytic agent Drugs 0.000 description 1
230000002537 thrombolytic effect Effects 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
General Chemical & Material Sciences (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

KR1020070035074A 2007-04-10 2007-04-10 락탐형 피리딘 화합물을 포함하는 허혈성 질환의 예방 및치료용 약학조성물 Ceased KR20080091948A (ko)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
KR1020070035074A KR20080091948A (ko)	2007-04-10	2007-04-10	락탐형 피리딘 화합물을 포함하는 허혈성 질환의 예방 및치료용 약학조성물
PCT/KR2008/002029 WO2008123755A1 (fr)	2007-04-10	2008-04-10	Compositions pharmaceutiques contenant des dérivés de pyridine de type lactame en tant que principe actif pour la prévention et le traitement de l'ischémie

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
KR1020070035074A KR20080091948A (ko)	2007-04-10	2007-04-10	락탐형 피리딘 화합물을 포함하는 허혈성 질환의 예방 및치료용 약학조성물

Publications (1)

Publication Number	Publication Date
KR20080091948A true KR20080091948A (ko)	2008-10-15

Family

ID=39831161

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
KR1020070035074A Ceased KR20080091948A (ko)	2007-04-10	2007-04-10	락탐형 피리딘 화합물을 포함하는 허혈성 질환의 예방 및치료용 약학조성물

Country Status (2)

Country	Link
KR (1)	KR20080091948A (fr)
WO (1)	WO2008123755A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200942537A (en)	2008-02-01	2009-10-16	Irm Llc	Compounds and compositions as kinase inhibitors
TW201105669A (en) *	2009-07-30	2011-02-16	Irm Llc	Compounds and compositions as Syk kinase inhibitors
WO2012088266A2 (fr)	2010-12-22	2012-06-28	Incyte Corporation	Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3
ES2984771T3 (es)	2012-06-13	2024-10-31	Incyte Holdings Corp	Compuestos tricíclicos sustituidos como inhibidores de FGFR
WO2014026125A1 (fr)	2012-08-10	2014-02-13	Incyte Corporation	Dérivés de pyrazine en tant qu'inhibiteurs de fgfr
WO2014051653A1 (fr) *	2012-09-27	2014-04-03	Portola Pharmaceuticals, Inc.	Inhibiteurs de kinase à base de dihydropyridone bicyclique
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
EA035095B1 (ru)	2013-04-19	2020-04-27	Инсайт Холдингс Корпорейшн	Бициклические гетероциклы в качестве ингибиторов fgfr
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
EA038045B1 (ru)	2015-02-20	2021-06-28	Инсайт Корпорейшн	Бициклические гетероциклы в качестве ингибиторов fgfr
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en)	2015-02-20	2017-02-28	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US11174257B2 (en)	2018-05-04	2021-11-16	Incyte Corporation	Salts of an FGFR inhibitor
RS66310B1 (sr)	2018-05-04	2025-01-31	Incyte Corp	Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
WO2020185532A1 (fr)	2019-03-08	2020-09-17	Incyte Corporation	Méthodes de traitement du cancer au moyen d'un inhibiteur de fgfr
WO2021007269A1 (fr)	2019-07-09	2021-01-14	Incyte Corporation	Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
WO2021067374A1 (fr)	2019-10-01	2021-04-08	Incyte Corporation	Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
PH12022550892A1 (en)	2019-10-14	2023-05-03	Incyte Corp	Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en)	2019-10-16	2023-01-31	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
AU2020395185A1 (en)	2019-12-04	2022-06-02	Incyte Corporation	Derivatives of an FGFR inhibitor
EP4069696A1 (fr)	2019-12-04	2022-10-12	Incyte Corporation	Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr
US12012409B2 (en)	2020-01-15	2024-06-18	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
JP2024513575A (ja)	2021-04-12	2024-03-26	インサイト・コーポレイション	Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
WO2022261160A1 (fr)	2021-06-09	2022-12-15	Incyte Corporation	Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr
TW202313610A (zh)	2021-06-09	2023-04-01	美商英塞特公司	作為ｆｇｆｒ抑制劑之三環雜環

2007
- 2007-04-10 KR KR1020070035074A patent/KR20080091948A/ko not_active Ceased
2008
- 2008-04-10 WO PCT/KR2008/002029 patent/WO2008123755A1/fr not_active Ceased

Also Published As

Publication number	Publication date
WO2008123755A1 (fr)	2008-10-16

Publication	Publication Date	Title
KR20080091948A (ko)	2008-10-15	락탐형 피리딘 화합물을 포함하는 허혈성 질환의 예방 및치료용 약학조성물
EP2609082B1 (fr)	2015-02-18	Imidazo[4,5-c]quinolines utilisés en tant qu'inhibiteurs d'adn-pk
KR101630432B1 (ko)	2016-06-15	2, 6-위치가 치환된 3-니트로피리딘 유도체 화합물 또는 이의 약제학적으로 허용되는 염을 포함하는 암 예방 또는 치료용 약학 조성물
CN105712991B (zh)	2017-12-01	7‑氮杂吲哚衍生物
CA2917742C (fr)	2020-04-14	Combinaison pharmaceutique pour le traitement du melanome
US8481553B2 (en)	2013-07-09	Antimetastatic compounds
DK2588457T3 (en)	2015-01-12	PYRAZOLOQUINOLINDERIVATER as DNA-PK inhibitors
US10738014B2 (en)	2020-08-11	2-substituted amino-naphth (1,2-d) imidazol-5-one compounds or pharmaceutically acceptable salts thereof
AU2018392985A1 (en)	2020-06-04	Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
US20190374536A1 (en)	2019-12-12	Methods of using fasn inhibitors
US9556154B2 (en)	2017-01-31	Pyrrole-substituted indolone derivative, preparation method therefor, composition comprising same and use thereof
CN110343033A (zh)	2019-10-18	厚朴酚系列衍生物及其制备方法和用途
US20220220106A1 (en)	2022-07-14	Quinoline compounds and pharmaceutical compositions and uses thereof
CA2761182A1 (fr)	2010-11-11	Flavones a substitution pyrrolidine en tant que radiosensibiliseurs a utiliser dans le traitement du cancer
CN114450285B (zh)	2024-04-09	用于治疗眼部病症的化合物
KR20080091949A (ko)	2008-10-15	락톤형 피리딘 화합물을 포함하는 허혈성 질환의 예방 및치료용 약학조성물
CN119095831A (zh)	2024-12-06	3-苯基异噁唑衍生物和含有其作为活性成分的用于预防或治疗眼部疾病的药物组合物
JP2005525999A (ja)	2005-09-02	原発性脳腫瘍または転移性脳腫瘍を治療または予防するためのベンゾピラノン誘導体の使用
CN115974719B (zh)	2025-01-07	化合物、包括所述化合物的药物组合物及其用途
JPWO2014157727A1 (ja)	2017-02-16	眼疾患治療剤
KR19990007796A (ko)	1999-01-25	혈관 신생 억제제
JP2008247878A (ja)	2008-10-16	イミダゾピリジンおよびイミダゾピリミジン化合物ならびにそれを含有する麻酔または鎮静薬組成物
US20170128449A1 (en)	2017-05-11	Medicinal composition inhibiting neovascularization proliferation factor
CN102171215B (zh)	2014-06-18	7H-咪唑并[1,2-a]吡喃并[2,3-c]吡啶类衍生物及其应用
CN118271305A (zh)	2024-07-02	苯并氮杂䓬酮类衍生物及其用途

Legal Events

Date	Code	Title	Description
2007-04-10	PA0109	Patent application	Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20070410
2008-10-15	PG1501	Laying open of application
2012-04-10	A201	Request for examination
2012-04-10	PA0201	Request for examination	Patent event code: PA02012R01D Patent event date: 20120410 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 20070410 Comment text: Patent Application
2013-09-17	E902	Notification of reason for refusal
2013-09-17	PE0902	Notice of grounds for rejection	Comment text: Notification of reason for refusal Patent event date: 20130917 Patent event code: PE09021S01D
2013-11-29	E601	Decision to refuse application
2013-11-29	PE0601	Decision on rejection of patent	Patent event date: 20131129 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20130917 Comment text: Notification of reason for refusal Patent event code: PE06011S01I